Aptar Pharma to Exhibit Innovative Drug Delivery Devices at Pharmapack 2018 in Paris, France

Image1

Aptar Pharma, a leading drug delivery systems provider, will once again be a key exhibitor at Pharmapack 2018, Europe’s dedicated pharmaceutical packaging and drug delivery event, which takes place on February 7-8 at Paris Expo, Porte de Versailles, France.

 

Aptar Pharma’s booth, located at Hall 7.1, Booth B24/B26, will present their diverse portfolio of drug delivery solutions and will showcase their latest technology innovations. A dedicated connectivity hub will center on the field of connected healthcare solutions, a significant megatrend, which can greatly improve patient behavior and adherence.

Pharmapack provides invaluable insight into the latest trends, developments and regulatory changes impacting the industry, as well as a wide variety of learning opportunities. This year, three of Aptar Pharma’s experts have been selected to share their specialist knowledge during Pharmapack.

Gerallt Williams, Director – Scientific Affairs at Aptar Pharma, will present Opportunities and Challenges of Drug Delivery Via the Nasal Route, on February 8 at 10.00 am in Conference Room 741.  Dr. Williams’ talk is part of Conference Session 3: How will New Drug Delivery Solutions Revolutionize Patient Life and Improve Treatment Adherence?

Arnaud Fournier, Senior Business Project Manager – Injectables will present a Learning Lab on February 7 at 11.30 am at Booth H2.  His talk, Setting the Standard for Film Coated Stoppers with an Unrivalled Reduction in Particulates will discuss injectable drug trends given today’s stricter regulatory requirements. With more sensitive drugs being developed, Mr. Fournier will share insight into the need for tighter quality standards and coated packaging solutions such as Aptar Pharma’s PremiumCoat™ coated stopper, which offers an unrivalled reduction in particulates.

Sai Shankar, Director Business Development – Connected Devices, will present a Learning Lab entitled Driving Better Patient Outcomes with Connectivity on February 7 at 15.50 at Booth H2. Mr. Shankar will discuss how patient behavior can be changed through connective, intuitive, user-friendly devices, which can significantly increase does adherence and improve patient health outcomes. He will also feature Aptar Pharma’s connected device portfolio which covers Application Fields such as Respiratory and Eye Care.

Aptar Pharma will also be a selected exhibitor on Pharmapack’s guided Innovation Tours on Thursday, February 8, at 10.30am at the Innovation Gallery. The Innovation Tours take visitors on a tour of highlighted exhibitors who have made innovative strides in the industry.

Visit Aptar Pharma during Pharmapack at Hall 7.1, Booth B24/B26, where their team of experts look forward to welcoming their valued customers and partners from around the world and to exchange with key opinion leaders in the industry.

With over 400 exhibitors and more than 5,000 Pharma & drug delivery professionals expected to attend Pharmapack this year, Aptar Pharma welcomes the opportunity to once again be a part of this important industry event.

Tekni-Films discusses latest in rigid and flexible packaging materials for medical device, pharma applications at MD&M West

teck

The latest in rigid and flexible packaging materials for medical device and pharmaceutical applications will be featured by Tekni-Films, a Tekni-Plex business unit, at MD&M West, February 6-8, Anaheim Convention Center, Anaheim, Calif., in Booth 2027.

Tekni-Films will be discussing its TekniMD® PX copolyester film series with grades that provide a cost effective alternative to PETG for thermoformed medical tray packaging. The company also offers a laminated alternative to PVC for thermoformed pharmaceutical blister applications.

 

Tekni-Films also will be displaying its ultra-high barrier PVDC coating and a wide variety of other multilayer packaging structures that deliver the stringent oxygen and water vapor barrier properties necessary to protect pharmaceutical and medical device products.

Doppelherz sparkles with new packaging from Sanner

sanner

In the highly competitive market for food supplements, effervescent tablets in tubes are considered one of the most effective and reliable dosage forms. In contrast to other packaging types, tubes do not crack or bend. The tablets cannot crumble; they are protected from light and moisture and have a long shelf life. The dietary supplements producer Queisser also relies on these advantages for the successful Doppelherz vitamins and minerals. Since the beginning of last year, customers receive an even more consumer-friendly and attractive packaging thanks to the Sanner Brilliance® tubes.


Holistic concept from a single source

Queisser supplies customers in Europe, Russia and Asia with effervescent tablets. The company has been using the proven and tested desiccant closures from Sanner for more than 15 years. In 2016, they decided to switch to in-mold-labeling technology to achieve higher quality printing result and, above all, an improved readability for consumers. “With the Sanner Brilliance® tubes, we offer our customers a high-end product in high-quality packaging,” says Jürgen Hennings, Product Manager Marketing at Queisser Pharma. “The brilliant printing results increase the readability of the printed information, while providing a high quality impression and more attention at point-of-sale.”
But these were not the only requirements: Queisser also needed a different tube length for the Doppelherz effervescent tablets. “Sanner was the only supplier able to promptly produce the according tube length with IML technology,” Hennings explains. Instead of the conventional 144 millimeters, the Doppelherz tubes are 165 millimeters long. Sanner developed a new IML-capable tool specifically for the production of these tubes. “The combination of flexibility, quality and trust, together with the well-known desiccant closures were determining factors for our decision,” says Hennings. The company now receives a holistic effervescent packaging solution from a single source.


Flexible packaging with brilliant design

Compared to conventional tubes printed with offset technology, IML tubes offer higher-quality, photorealistic printing with different surface structures. Up to eight colors and real metallic effects are possible. The good readability of the label, even for smaller font sizes, provides more space for product information, while the impact- and scratch-resistant decor ensures long durability.
The packaging can also be upgraded with additional features: consumers receive more detailed information via QR codes with just one click, while peel-off labels can be used as an additional information booklet. This way, customers get an attractive packaging with all the information they require in a small space – and manufacturers can increase brand loyalty thanks to a high-quality appearance and exceptional user-friendliness.

Mérieux Développement and Gimv announce the signature of an exclusivity agreement with a view to acquiring Stiplastics Healthcaring

stiplastics

Mérieux Développement and Gimv, together with the management team, announce that they have signed an exclusivity agreement with Stage Capital, Stiplastics Healthcaring’s majority shareholder, with a view to acquiring the company.

Stiplastics Healthcaring, which was founded in 1985 and has been owned by Stage Capital (formerly NBGI) since 2013, designs, develops and manufactures standard and smart plastic solutions for the pharmaceutical industries and the health sector. Based in Saint-Marcellin (Isère – France), the company currently employs over 90 people on a 10,000 m2 industrial site opened last October. The Group expects to achieve turnover of EUR 21 million in the current 2017/2018 financial year, 98% of which will be generated by the health sector. Exports account for 55% of Stiplastics’ turnover, thanks to its development of devices for the dispensing of solid-form medications (especially in the USA).

Stiplastics Healthcaring has over 30 years’ experience in medical plastics. It works with customers throughout the entire process, from formulating the exact needs until the product is launched. It is a recognised specialist in the area of treatment observance, and its range of “intelligent” pill dispensers encourage treatment observance, and make administering and taking medicines easier and safer. It has also built solid expertise in solutions for respiratory diseases. Stiplastics Healthcaring works in partnership with pharmaceutical industry leaders and has recently developed an inhalation device.

The company has a strong development potential in the connected health sector, with new products in the pipeline and a modern workshop for the production of electronic products in a controlled environment. In order to meet the new needs of patients and healthcare actors faced with changing pathologies and uses, and more specifically the increasing prominence of connected care, the Group has set up its IoC [Internet Of Care]® unit, which is dedicated to designing, developing and producing e-health medical devices. In addition, several partnership agreements were finalised in 2017 in what is an extremely promising sector, which will benefit patients and practitioners alike.

Mérieux Développement and Gimv1 have joined forces to acquire Stiplastics Healthcaring. They will contribute their complementary expertise in the health sector and support the growth of this French company. Stiplastics Healthcaring will remain under the operational management of Jérôme Empereur and Laetitia Le Gall, who have successfully developed this high-performing industrial platform, whilst creating real sales momentum in recent years.

“The Mérieux Développement – Gimv consortium is an ideal tandem that will allow Stiplastics Healthcaring to grow further and accelerate its development. They bring to the table health sector specialists as well as substantial financial resources, which is perfectly suited to support the
Group’s growth challenges” explained Jérôme Empereur, Stiplastics Healthcaring’s Chairman-CEO. “Our decision to invest in Stiplastics Healthcaring is based on our assessment of the strength of the management team and our shared ambition on the company’s future. In particular, we have jointly identified the increased need for innovative solutions to improve observance and administration of medicines. We are delighted to be the new reference shareholder of this French company and to be given this opportunity to support its innovative strategy and international development plans.” says Jean-François Billet, Senior Partner at Mérieux Développement.

“Stiplastics Healthcaring has all the necessary assets to become a European market leader, including cutting-edge production facilities, excellent regulatory expertise and a deep understanding of its clients’ needs. We are very proud that Jérôme Empereur and the entire management team have chosen the Mérieux Développement-Gimv consortium to support them in their ambitious growth plans,” adds Benoit Chastaing, Partner Health & Care at Gimv.

The transaction is expected to close by the end of January 2018. No further financial details about this transaction will be disclosed.

Union Plastic presents its new innovative applicator cap APPLISIL® for vaginal cream

union-plastic

Union Plastic is specialized from the design to the manufacturing of medical device and pharmaceutical primary packaging.

Developed in partnership with laboratories and end-users for 6 months, the company launches during PHARMAPACK 2018 a new innovative applicator cap for its APPLISIL® range of product.

This new innovative cap improves traditional devices with its reinforced hygiene, security and ease of use.

 

 

The applicator cap APPLISIL® allows a 2 in 1 use: an adaptable side to the main vaginal cream tubes and a side suitable to the vaginal applicators APPLISIL® (dosage from 0.5 to 5 ml).
img1
This new product has a lot of advantages:

– Total absence of particle discharges (aluminum and/or plastic)
– Resealable stopper
– Adaptable to several aluminum tube diameters
– Reinforced hygiene
– Adaptable to the applicators APPLISIL®
– Tamper evident in option

The cap applicator APPLISIL® has got a patent registration and will be marketed from the second half-year 2018.

The future is now – Pharmapack Europe 2018 to showcase evolution and revolution in packaging and drug delivery

800-600_pharmapack

Pharmapack Europe 2018, Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition, takes place on 7 & 8 February at Paris Expo Porte de Versailles, Paris. The packed event programme includes key note speeches from leading industry figures, a symposium, educational workshops, and a learning lab that will explore regulatory changes and impacts, challenges in packaging & devices development: biologics, materials, sustainability and quality consistency, and how new patient-centric innovations in drug delivery will revolutionise lives and improve treatment adherence. Furthermore, new for Pharmapack Europe 2018 is the Start-up Pitch, a unique opportunity for companies at an early stage or pre-commercialisation phase to present their idea in front of industry experts.

Pharmapack Europe is an essential event for industry insights and the latest industry innovations that are reimagining the capabilities of pharmaceutical packaging and drug delivery. One area that provides opportunities and challenges is biologics, a growth area for the pharmaceutical industry both now and in the future with biologics representing 70% of drugs currently in development. Pharmapack Europe 2018 will include keynote presentations on the key factors for successful collaboration on pharmaceutical packaging development for biologics, speeches on integrated approaches towards the design of drug delivery platforms for biologics, and case studies assessing delivery options for injectable biologics. In addition, patient-centric considerations provide new avenues of innovation in drug delivery solutions. Sessions will be dedicated to innovations in packaging that improve patients’ lives, identifying new areas of opportunity in designing the future of drug delivery packaging, and practical solutions to help stakeholders innovate in this area.

The 2018 Start-up Hub will showcase young companies as being amongst the most innovative in the industry. Companies in the Start-up Hub will benefit from increased access to potential customers, partners and investors at Pharmapack Europe 2018 from which to forge new and lasting relationships. New for 2018 is the Start-up Pitch, offering non-commercialised companies the opportunity to present in front of a start-up panel of experts and an audience of industry professionals. The Start-up Hub and Start-up Pitch are organised in collaboration with Early Metrics, the pan-European rating agency for start-ups and innovative SMEs, assessing the potential growth of early stage ventures by analysing a company’s non-financial metrics.

Register now for free! : https://registration.n200.com/survey/3l2lujn6zr6dx?actioncode=PAR1241

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

800-600_novartis_sandoz

Sandoz, a Novartis division has announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company’s strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America and the EU, while Biocon will lead commercialization in Rest of the World.

“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Richard Francis, CEO, Sandoz. “Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics.”

“Together, we will be able to realize benefits at every stage of the value chain, from development, through manufacturing to commercialization,” said Carol Lynch, Global Head, Biopharmaceuticals, Sandoz. “This collaboration further strengthens our ability to deliver next-generation biosimilar medicines to patients.”

Sandoz is committed to increasing patient access to high-quality biosimilars. We are the global leader in biosimilars, with five biosimilars currently marketed worldwide, as well as a leading global pipeline. Sandoz is well-positioned to continue leading the biosimilars industry based on our experience and capabilities in development, manufacturing and commercialization. As a division of Novartis, the first global healthcare company to establish a leading position in both innovative and off-patent medicines, we benefit strongly from this unique blend of experience and expertise in many different market environments.

As an innovation-led biopharmaceutical company, Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from ‘lab to market’. The collaboration with Sandoz builds upon Biocon’s successful progress in its existing global biosimilars program. An early mover in the biosimilars space, Biocon has successfully launched its insulin glargine in Japan, trastuzumab and bevacizumab biosimilars in India and rh-insulin, insulin glargine and biosimilar trastuzumab in a few emerging markets; and it was the first Indian company to have a biosimilar approved by the US Food and Drug Administration.

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment

800-600_roche

Roche has announced a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients.

The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.

For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.

“This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” said Roland Diggelmann, CEO Roche Diagnostics.

Roche Diagnostics is the global leader in in-vitro diagnostics, and GE Healthcare is a worldwide leader in medical imaging equipment. “This is the first time that two major players in healthcare have combined digital, in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry,” said Kieran Murphy, President & CEO of GE Healthcare.

A bag full of novelties: Sanner at Pharmapack 2018

sanner

At Pharmapack Europe in Paris, visitors to booth C46-47 can see the whole range of desiccant solutions from Sanner, the manufacturer of high-quality primary plastic packaging and medical devices. In addition to integrated desiccants, Sanner presents its innovative drop-in solutions AdPack® and AdCap®. The AdPack® desiccant sachets made of Tyvek® material offer an ideal combination of breathability, moisture protection and durability. The desiccant capsules AdCap®, in turn, combine the advantages of conventional capsules and canisters, while offering high stability and a 30-percent higher moisture adsorption. Their unique grid structure enables 360-degree moisture adsorption and prevents mistakes during ingestion.

Tekni-Plex held successful grand opening at new China manufacturing facility

tekniplex

More than 40 government officials and 60 representatives from pharmaceutical and medical device companies attended the recent grand opening celebration for Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai. Plant tours and a luncheon followed the opening ceremony. Earlier this year, Tekni-Plex announced a $15 million investment in the facility to support the growing needs of the Asia-Pacific pharmaceutical and medical device markets that are supported with products developed by Tekni-Plex’s Colorite, Natvar and Action Technology business units.

Tekni-Plex senior management in attendance at the ribbon cutting included Paul Young, chief executive officer; Russell Hubbard, vice president-international and general manager; Ian Kenny, global managing director, Colorite; Johan Laureys, global vice president of Action Technology, and Bob Donohue, general manager of the company’s Natvar business unit. Xu Xiaofeng, standing committee member of CPC Wujiang Committee and deputy party secretary and vice chairman for Wujiang government, was also in attendance.

The more than 140,000-square-foot (13,000-square-meter) facility is manufacturing Tekni-Plex’s Natvar, Colorite and Action Technology products. The facility features three Class 100K cleanrooms to accommodate medical-grade tubing and components production plus one Class 10K cleanroom that will produce Natvar’s pharma-grade tubing.

The facility is in the process of commercializing Natvar’s recently-announced silicone extrusion tubing for catheters, feeding tubes, drug delivery and peristaltic pump applications. Production for microextrusion tubing that targets a wide variety of demanding neurovascular interventional therapies and surgical applications is expected to be on stream early next year. The facility will also manufacture Colorite custom compounds for medical device applications, and Action Technology’s dip tubes used in a wide variety of food/beverage, pharmaceutical, personal care, industrial and household pump applications.